indication

Schizophrenia; Psychosis

Competitive landscape

as of 2026-07-01
Competitive set
5
4 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
54 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugNot Yet Recruiting
Xanomeline-trospium (Cobenfy)
US-approved 2024 · Cobenfy
Phase 33 trials
OwnerKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Protection2039
drugRecruiting
Lumateperone (Caplyta)
US-approved 2019 · CAPLYTA
Phase 31 trial
OwnerIntra-Cellular Therapies, Inc.
Protection2040
drugRecruiting
Risperidone
US-approved 1993 · RISPERDAL
Phase 31 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugUnknown
Haloperidol
US-approved 1986 · Haldol Decanoate
—1 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Flupentixol
Pipeline · Phase 4
Phase 41 trial
OwnerTechnical University of Munich
Protection—

Market size

prevalence as a range, not a number